Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Operating Expenses for 7 consecutive years, with $136.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 49.98% to $136.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $461.6 million through Dec 2025, up 25.76% year-over-year, with the annual reading at $461.6 million for FY2025, 25.76% up from the prior year.
  • Operating Expenses hit $136.7 million in Q4 2025 for Harmony Biosciences Holdings, up from $114.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $136.7 million in Q4 2025 to a low of $34.7 million in Q1 2021.
  • Historically, Operating Expenses has averaged $74.7 million across 5 years, with a median of $69.3 million in 2023.
  • Biggest five-year swings in Operating Expenses: dropped 22.93% in 2023 and later soared 91.5% in 2024.
  • Year by year, Operating Expenses stood at $44.8 million in 2021, then rose by 20.21% to $53.8 million in 2022, then soared by 58.08% to $85.1 million in 2023, then rose by 7.13% to $91.1 million in 2024, then surged by 49.98% to $136.7 million in 2025.
  • Business Quant data shows Operating Expenses for HRMY at $136.7 million in Q4 2025, $114.3 million in Q3 2025, and $114.2 million in Q2 2025.